...
【24h】

Interactions between the amyloid and cholinergic mechanisms in Alzheimer's disease.

机译:淀粉样蛋白和胆碱能机制在阿尔茨海默氏病中的相互作用。

获取原文
获取原文并翻译 | 示例
           

摘要

Alzheimer's disease (AD) is a progressive, neurodegenerative disease characterized by memory and cognitive loss, the formation of senile plaques containing amyloid-beta (Abeta) peptide, degeneration of the cholinergic neurons and the development of neurofibrillary tangles. The build-up of Abeta is considered to be a central feature in the pathogenesis of AD. However, other critical molecular and neurochemical alterations too occur, such as a cholinergic dysfunction. As concerns the pathomechanism of the disease, both the amyloid cascade hypothesis and the cholinergic hypothesis of AD are widely accepted. This review surveys recent in vitro and in vivo experimental evidence relating to these two hypotheses. Bidirectional pathways linking them as regards the cholinergic neurotoxicity of Abeta and the regulatory mechanisms of cholinergic receptor activation or enzyme inhibition in the processing of the amyloid precursor protein are also discussed. Further work is warranted to elucidate the exact effects in the interactions between the cholinergic and amyloid hypotheses of the candidate drugs used in AD therapy.
机译:阿尔茨海默氏病(AD)是一种进行性神经退行性疾病,其特征在于记忆力和认知丧失,含有淀粉样β(Abeta)肽的老年斑形成,胆碱能神经元变性和神经原纤维缠结的发展。 Abeta的积累被认为是AD发病机理的主要特征。但是,也会发生其他关键的分子和神经化学改变,例如胆碱能功能障碍。关于疾病的发病机理,AD的淀粉样蛋白级联假说和胆碱能假说都被广泛接受。这篇综述调查了与这两个假设有关的最新的体外和体内实验证据。还讨论了在Aβ的胆碱能神经毒性和淀粉样蛋白前体蛋白加工过程中胆碱能受体激活或酶抑制的调节机制相关的双向途径。有必要做进一步的工作来阐明AD治疗中候选药物的胆碱能和淀粉样蛋白假说之间相互作用的确切作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号